Zydus Receives Tentative Approval from the USFDA for Esomeprazole Magnesium Delayed- Release Capsules USP

Deepthi | Myequity news | Date : 21-01-2019 15:30:00 IST

Zydus Cadila has received the tentative approval from the USFDA to market Esomeprazole Magnesium Delayed- release Capsules (US RLD — NEXIUM). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Esomeprazole belongs to the group of medicines termed as proton pump inhibitors. Esomeprazole reduces the amount of acid secreted by the stomach. The drug is used to treat the symptoms of gastroesophageal reflux disease, to reduce the risk of stomach ulcers in some people taking pain medicines, treat patients with stomach infection (Helicobacter pylori) along with certain antibiotics and long-term treatment of conditions where stomach makes too much acid.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

More from Myequity